Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer

British Journal of Cancer

Volumn 106, Issue 7, 2012, Pages 1249-1258

  Aapro, M ^a   Jelkmann, W ^b   Constantinescu, S N ^c   Leyland Jones, B ^d  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

disease progression; erythropoiesis stimulating agents; erythropoietin receptor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TAXANE DERIVATIVE; VINCRISTINE;

ANEMIA; B CELL LYMPHOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DRUG SAFETY; ERYTHROPOIESIS; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MORTALITY; MULTIPLE MYELOMA; NEOPLASM; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TISSUE OXYGENATION; VENOUS THROMBOEMBOLISM;

ANEMIA; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; HEMATINICS; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS; RECEPTORS, ERYTHROPOIETIN;

EID: 84859218749     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.42     Document Type: Review

References (113)

1. Aapro M, Barnadas A, Leonard RC, Marangolo M, Untch M, Ukarma L, Burger HU, Scherhag A, Osterwalder B (2009a) What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta? Eur J Cancer 45: 2984-2991
2. Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU (2008) Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline-and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 26: 592-598 (Pubitemid 351264353)
3. Aapro M, Osterwalder B, Scherhag A, Burger HU (2009b) Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer 101: 1961-1971
4. Ait-Oudhia S, Scherrmann JM, Krzyzanski W (2010) Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats. J Pharmacol Exp Ther 334: 897-910
5. Akan H, Guven N, Aydogdu I, Arat M, Beksac M, Dalva K (2000) Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis. Acta Haematol 103: 152-156
6. Amgen (2008) Amgen Inc. in collaboration with Johnson & Johnson Pharmaceutical Research and Development, L.L.C.Background Information. For The Oncologic Drugs Advisory Comittee (ODAC) Meeting. 13 March 2008 available from http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-00-FDA-index.htm
7. Amgen. Aranesps(Darbepoetin alfa) Package Insert. Amgen Inc., Thousand Oaks, CA, (2011)
8. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M (1990) Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87: 5978-5982
9. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 91: 3974-3978 (Pubitemid 24139555)
10. Bahlmann FH, DeGroot K, Duckert T, Niemczyk E, Bahlmann E, Boehm SM, Haller H, Fliser D (2003) Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 64: 1648-1652 (Pubitemid 37323692)
11. Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Byrne J, Menchaca DM, Fox RM, Begley CG (1997) Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 89: 3118-3128
12. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299: 914-924 (Pubitemid 351397066)
13. Blohmer J-U, Wurschmidt F, Petry U, Weise G, Sehouli J, Kimming R, Dressler P, Kentenich H, Kohls A, Lichtenegger W (2004) Results with sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer: Results of a prospective, randomized, open and controlled AGO-and NOGGO-intergroup study. Ann Oncol 15(Suppl 3): 128
14. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A (2009) Recombinant human erythropoiesis- stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373: 1532-1542
15. Boogaerts M, Oberhoff C, Ten Bokkel Huinink W, Nowrousian MR, Hayward CR, Burger HU (2006) Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis. Anticancer Res 26: 479-484 (Pubitemid 43206005)
16. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T (1991) Erythropoietin receptor characteristics on primary human erythroid cells. Blood 77: 2583-2590
17. Brown WM, Maxwell P, Graham AN, Yakkundi A, Dunlop EA, Shi Z, Johnston PG, Lappin TR (2007) Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 25: 718-722 (Pubitemid 46354231)
18. Buss DH, Cashell AW, O'Connor ML, Richards 2nd F, Case LD (1994) Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med 96: 247-253 (Pubitemid 24099224)
19. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91: 2214-2221 (Pubitemid 32552805)
20. Cella D, Kallich J, McDermott A, Xu X (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 15: 979-986 (Pubitemid 39004357)
21. Centocor Ortho Biotech Products (2011) Procrits (Epoetin alfa) Package Insert. Centocor Ortho Biotech Products, L.P.: Raritan, NJ
22. Chang J, Couture F, Young S, McWatters KL, Lau CY (2005) Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23: 2597-2605 (Pubitemid 46179448)
23. Delarue R, Haioun C, Coiffier B, Fornecker L, Fournier M, Mounier N, Molina TJ, Bologna S, Fruchart C, Picard S, Tilly H, Bosly A (2011) Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study. J Clin Oncol 29(Suppl 15): abstract 9048
24. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31: 290-299 (Pubitemid 36407605)
25. Egrie JC, Strickland TW, Lane J, Aoki K, Cohen AM, Smalling R, Trail G, Lin FK, Browne JK, Hines DK (1986) Characterization and biological effects of recombinant human erythropoietin. Immunobiology 172: 213-224 (Pubitemid 16004076)
26. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, Spahr C, Um M, Van G, Begley CG (2006) Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107: 1892-1895 (Pubitemid 43289368)
27. Elliott S, Busse L, McCaffery I, Rossi J, Sinclair A, Spahr C, Swift S, Begley CG (2010) Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J Immunol Methods 352: 126-139
28. eMC (2011) Electronic Medicines Compendium (eMC) website Available from http://emc.medicines.org.uk
29. EMEA (2011) European public assessment reports for authorised medicinal products for human use. European Medicines Agency website Available from http://www.emea.europa.eu/htms/human/epar/a.htm
30. Engert A, Diehl V, Stein H, Mueller R-P, Eich H, Dietlein M, Paulus U, Pfistner B, Josting A, Borchmann P, Fuchs M, Haferkamp H, Nisters-Backes H, Koch B (2007) Role of erythropoetin (EPO) in patients with Hodgkin lymphoma. Paper presented at The 7th International Symposium on Hodgkin Lymphoma; November 3-7, 2007; Cologne, Germany
31. Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sokler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V (2010) Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 28: 2239-2245
32. Farrell F, Lee A (2004) The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9: 18-30 (Pubitemid 39658342)
33. Fraser JK, Lin FK, Berridge MV (1988) Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, HEL. Exp Hematol 16: 836-842
34. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H (2010) Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 102: 301-315
35. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616-1634 (Pubitemid 29479929)
36. Grossi A, Vannucchi AM, Rafanelli D, Rossi Ferrini P (1989) Recombinant human erythropoietin has little influence on megakaryocytopoiesis in mice. Br J Haematol 71: 463-468 (Pubitemid 19121326)
37. Grote T, Yeilding AL, Castillo R, Butler D, Fishkin E, Henry DH, DeLeo M, Fink K, Sullivan DJ (2005) Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 23: 9377-9386
38. Gupta S, Singh PK, Bisth SS, Bhatt ML, Pant M, Gupta R, Singh S, Negi MP (2009) Role of recombinant human erythropoietin in patients of advanced cervical cancer treated 'by chemoradiotherapy'. Cancer Biol Ther 8: 13-17
39. Hadland BK, Longmore GD (2009) Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J Clin Oncol 27: 4217-4226
40. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ, Darbepoetin alfa 20000161 Study Group (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122: 394-403 (Pubitemid 36951623)
41. Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG (2005) Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, doubleblind, placebo-controlled trials. J Clin Oncol 23: 6941-6948
42. Hedley BD, Chu JE, Ormond DG, Beausoleil MS, Boasie A, Allan AL, Xenocostas A (2011) Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models. Clin Cancer Res 17: 6151-6162
43. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102: 1340-1346 (Pubitemid 36988041)
44. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260 (Pubitemid 37324251)
45. Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, Pajonk F (2006) Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24: 4708-4713 (Pubitemid 46630934)
46. Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI (2009) Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 101: 1633-1641
47. Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K, Gaffney C (2009) Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J Clin Oncol 27: 5751-5756
48. Huang LJ, Constantinescu SN, Lodish HF (2001) The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 8: 1327-1338 (Pubitemid 34085003)
49. Ishii T, Bruno E, Hoffman R, Xu M (2006) Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 108: 3128-3134
50. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH (2002) Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64: 326-333
51. Jelkmann W (2010) Biosimilar epoetins and other 'follow-on' biologics: update on the European experiences. Am J Hematol 85: 771-780
52. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ (2008) The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 67: 39-61
53. Johnson & Johnson Pharmaceutical Research and Development LLC (2004) Safety of erythropoietin receptor agonists (ERAs) in patients with cancer. Background Information for Oncologic Drugs Advisory Committee Meeting 4 May 2004. Available from http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037b2.htm
54. Katodritou E, Verrou E, Hadjiaggelidou C, Gastari V, Laschos K, Kontovinis L, Kapetanos D, Constantinou N, Terpos E, Zervas K (2008) Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 83: 697-701
55. Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111: 4922-4929
56. Kim SN, Moon JH, Kim JG, Chae YS, Cho YY, Lee SJ, Kim YJ, Lee YJ, Suh JS, Lee KS, Sohn SK (2009) Mobilization effects of G-CSF, GM-CSF, and darbepoetin-alpha for allogeneic peripheral blood stem cell transplantation. J Clin Apher 24: 173-179
57. Klein HG, Spahn DR, Carson JL (2007) Red blood cell transfusion in clinical practice. Lancet 370: 415-426 (Pubitemid 47176657)
58. Koury MJ, Bondurant MC (1988) Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells. J Cell Physiol 137: 65-74
59. LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX (2006) Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5: 347-355
60. Laugsch M, Metzen E, Svensson T, Depping R, Jelkmann W (2008) Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 122: 1005-1011 (Pubitemid 351213997)
61. Leyland-Jones B (2003) BEST Investigators and Study Group: breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4: 459-460 (Pubitemid 37009952)
62. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960-5972
63. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z (2010) Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18: 423-435
64. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865-2874 (Pubitemid 32538196)
65. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA (2009) Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 27: 2838-2847
66. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40: 2293-2306 (Pubitemid 39348881)
67. Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, Stripp DC, Cmelak AJ, Schulsinger A, Fu KK (2007) Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys 69: 1008-1017 (Pubitemid 47625834)
68. Milroy R, Scagliotti G, van den Berg PM, Galanis NE, Gomez RG, Greil R, Krzakowski M (2003) Early intervention with epoetin alfa maintains hemoglobin (HB) in advanced non-small-cell lung cancer (NSCLC) patients. Lung Cancer 41(Suppl 2): S74
69. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N (2001) Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 98: 5181-5186 (Pubitemid 32397103)
70. Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28: 2874-2880
71. Moebus V, Lueck H, Thomssen C, Harbeck N, Nitz U, Kreienberg R, Jackisch C, Schneeweiss A, Huober J, du Bois A, Untch M (2007) The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: mature results of an AGO phase III study (ETC trial). J Clin Oncol 25(Suppl 18): abstract 569
72. Muller-Ehmsen J, Schmidt A, Krausgrill B, Schwinger RH, Bloch W (2006) Role of erythropoietin for angiogenesis and vasculogenesis: from embryonic development through adulthood. Am J Physiol Heart Circ Physiol 290: 331-340
73. Nagel S, Kellner O, Engel-Riedel W, Guetz S, Schumann C, Gieseler F, Schuette W (2011) Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. Clin Lung Cancer 12: 62-69
74. Nairz M, Schroll A, Moschen AR, Sonnweber T, Theurl M, Theurl I, Taub N, Jamnig C, Neurauter D, Huber LA, Tilg H, Moser PL, Weiss G (2011) Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kB-inducible immune pathways. Immunity 34: 61-74
75. Nitz U, Gluz O, Oberhoff C, Reimer T, Schumacher C, Hackmann J, Warm M, Uleer C, Runde V, Kuemmel S, Zuna I, Harbeck N (2011) Adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: survival and quality of life analysis from the prospective randomized WSG ARA Plus trial. Paper presented at The 34th San Antonio Breast Cancer Symposium; December 6-10, 2011; San Antonio, United States
76. Osterborg A, Aapro M, Cornes P, Haselbeck A, Hayward CR, Jelkmann W (2007) Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 43: 510-519 (Pubitemid 46177584)
77. Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma-a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 87: 2675-2682 (Pubitemid 26102216)
78. Osterborg A, Brandberg Y, Hedenus M (2005) Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 129: 206-209 (Pubitemid 40562441)
79. Overgaard J, Hoff C, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Johansen J, Andersen LJ, Evensen JF (2010) Randomized study of Aranesp as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)-Final outcome of the DAHANCA 10 trial. Radiother Oncol 96(Suppl 15): abstract 197
80. Overgaard J, Hoff C, Sand Hansen H, Specht L, Overgaard M, Grau C, Andersen E, Johansen J, Andersen L, Evensen J (2007) Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp s) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)-the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer 5(Suppl 7): 7
81. Pawlak K, Pawlak D, Mysliwiec M (2007) Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. Thromb Res 120: 797-803 (Pubitemid 47418236)
82. Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF (2008) Safety and efficacy of darbepoetin alfa in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 26: 2342-2349
83. Pronzato P, Cortesi E, van der Rijt C, Moreno-Nogueira A, Raimundo D, Ostler P, Bols A, Rosso R (2002) Early intervention with epoetin alfa in breast cancer (BC) patients (pts) undergoing chemotherapy (CT): Results of a randomized, multicenter, phase IIIb study (EPO-INT-47 Study Group). Ann Oncol 13(Suppl 5): 168
84. Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA (2005) Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. Curr Med Res Opin 21: 1527-1533 (Pubitemid 41505019)
85. Ribatti D (2010) Erythropoietin and tumor angiogenesis. Stem Cells Dev 19: 1-4
86. Rossi J, McCaffery I, Paweletz K, Tudor Y, Elliott S, Fitzpatrick VD, Patterson SD (2009) Analysis of cell surface erythropoietin receptor (EpoR) expression and function in human epithelial tumor tissues. J Clin Oncol 27(Suppl 15): abstract 11104
87. Seidel HM, Lamb P, Rosen J (2000) Pharmaceutical intervention in the JAK/STAT signaling pathway. Oncogene 19: 2645-2656 (Pubitemid 30339221)
88. Seidenfeld J, Piper M, Bohlius J, Weingart O, Trelle S, Engert A, Skoetz N, Schwarzer G, Wilson J, Brunskill S, Hyde C, Bonnell C, Ziegler KM, Aronson N (2006) Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Comparative Effectiveness Review No. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026). Agency for Healthcare Research and Quality: Rockville, MD. May 2006 Available from http://effectivehealthcare.ahrq.gov/repFiles/EPO%20Final.pdf
89. Shander A, Spence RK, Auerbach M (2010) Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents? Transfusion 50: 719-732
90. Sinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, Liu L, Busse L, Swift S, Elliott S, Begley CG (2010) Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 115: 4264-4272
91. Sinclair AM, Rogers N, Busse L, Archibeque I, Brown W, Kassner PD, Watson JEV, Arnold GE, Nguyen KCQ, Powers S, Elliott S (2008) Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 98: 1059-1067 (Pubitemid 351399799)
92. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG (2007) Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 110: 477-488 (Pubitemid 47106135)
93. Smith Jr RE, Aapro MS, Ludwig H, Pinter T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA (2008) Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26: 1040-1050
94. Strauss HG, Haensgen G, Dunst J, Hayward CR, Burger HU, Scherhag A, Koelbl H (2008) Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. Int J Gynecol Cancer 18: 515-524 (Pubitemid 351668300)
95. Swift S, Ellison AR, Kassner P, McCaffery I, Rossi J, Sinclair AM, Begley CG, Elliott S (2010) Absence of functional EpoR expression in human tumor cell lines. Blood 115: 4254-4263
96. Taniguchi N, Nakamura T, Sawada T, Matsubara K, Furukawa K, Hadase M, Nakahara Y, Matsubara H (2010) Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebocontrolled study. Circ J 74: 2365-2371
97. Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P (1998) Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 78: 752-756 (Pubitemid 28418307)
98. Thomas G, Ali S, Hoebers FJ, Darcy KM, Rodgers WH, Patel M, Abulafia O, Lucci 3rd JA, Begg AC (2008) Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dl with erythropoietin vs above 10.0 g/dl without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 108: 317-325
99. Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, Wiebe N, Klarenbach S (2009) Benefits and harms of erythropoiesisstimulating agents for anemia related to cancer: a meta-analysis. CMAJ 180: 62-71
100. Um M, Gross AW, Lodish HF (2007) A 'classical' homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 19: 634-645 (Pubitemid 46107815)
101. Untch M, Fasching PA, Bauerfeind I, Conrad U, Camara O, Fett W, Kuzeder W, Lück H, Loibl S, Von Minckwitz G (2008) PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, doseintensified chemotherapy with epirubicin, paclitaxel, and CMF with a standard dosed epirubicin/ cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery. J Clin Oncol 26(Suppl 15): abstract 517
102. Untch M, Fasching PA, Konecny GE, von Koch F, Conrad U, Fett W, Kurzeder C, Luck HJ, Stickeler E, Urbaczyk H, Liedtke B, Salat C, Harbeck N, Muller V, Schmidt M, Hasmuller S, Lenhard M, Schuster T, Nekljudova V, Loibl S, von Minckwitz G (2011a) PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, doseintensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel { +-} darbepoetin alfa in primary breast cancer-results at the time of surgery. Ann Oncol 22: 1988-1998
103. Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C, Luck HJ, Stickeler E, Urbaczyk H, Liedtke B, Beckmann MW, Salat C, Harbeck N, Muller V, Schmidt M, Hasmuller S, Lenhard M, Nekljudova V, Loibl S, Fasching PA (2011b) PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standarddosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis. Ann Oncol 22: 1999-2006
104. Vadhan-Raj S, Skibber JM, Crane C, Bueso-Ramos CE, Rodriguez-Bigas MA, Feig BW, Lin EH, Ajani JA, Collard M, Johnson MM, Hamilton SR, JanJan N (2004) Randomized, double-blind, placebo-controlled trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT/RT) followed by surgery: Early termination of the trial due to increased incidence of thrombo-embolic events (TEE). Blood 104: abstract 2915
105. van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ (2004) Erythropoietin in cardiovascular diseases. Eur Heart J 25(4): 285-291 (Pubitemid 38295436)
106. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211-1220 (Pubitemid 34993871)
107. Wagner LM, Billups CA, Furman WL, Rao BN, Santana VM (2004) Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J Clin Oncol 22: 1886-1893 (Pubitemid 41095180)
108. Wilkinson PM, Antonopoulos M, Lahousen M, Lind M, Kosmidis P (2006) Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer 94: 947-954
109. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74: 227-236 (Pubitemid 23221699)
110. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23: 2606-2617 (Pubitemid 46179449)
111. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25: 1027-1032 (Pubitemid 46596751)
112. Yonemura Y, Kawakita M, Fujimoto K, Sakaguchi M, Kusuyama T, Hirose J, Kato K, Takatsuki K (1992) Effects of short-term administration of recombinant human erythropoietin on rat megakaryopoiesis. Int J Cell Cloning 10: 18-27
113. Zwezdaryk KJ, Coffelt SB, Figueroa YG, Liu J, Phinney DG, LaMarca HL, Florez L, Morris CB, Hoyle GW, Scandurro AB (2007) Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells. Exp Hematol 35: 640-652 (Pubitemid 46427969)